Airway	O
Microbiota	B-OG
in	O
Severe	O
Asthma	B-DS
and	O
Relationship	O
to	O
Asthma	B-DS
Severity	O
and	O
Phenotypes	O

Competing	O
Interests	O
:	O
The	O
authors	O
have	O
declared	O
that	O
no	O
competing	O
interests	O
exist	O
.	O

Conceived	O
and	O
designed	O
the	O
experiments	O
:	O
WC	O
MM	O
KFC	O
QZ	O
.	O

Performed	O
the	O
experiments	O
:	O
QZ	O
MC	O
ZL	O
FB	O
RD	O
.	O

Analyzed	O
the	O
data	O
:	O
MC	O
WC	O
MM	O
QZ	O
.	O

Contributed	O
reagents	O
/	O
materials	O
/	O
analysis	O
tools	O
:	O
PC	O
PB	O
MC	O
.	O

Wrote	O
the	O
paper	O
:	O
KFC	O
WC	O
MM	O
MC	O
.	O

‡	O
These	O
authors	O
are	O
joint	O
senior	O
authors	O
on	O
this	O
work	O
.	O

Background	O

The	O
lower	O
airways	O
harbor	O
a	O
community	O
of	O
bacterial	O
species	O
which	O
is	O
altered	O
in	O
asthma	B-DS
.	O

Objectives	O

We	O
examined	O
whether	O
the	O
lower	O
airway	O
microbiota	B-OG
were	O
related	O
to	O
measures	O
of	O
asthma	B-DS
severity	O
.	O

Methods	O

We	O
prospectively	O
recruited	O
26	O
severe	O
asthma	B-DS
,	O
18	O
non	O
-	O
severe	O
asthma	B-DS
and	O
12	O
healthy	O
subjects	O
.	O

DNA	O
was	O
extracted	O
from	O
induced	O
sputum	O
and	O
PCR	O
amplification	O
of	O
the	O
V3	O
-	O
V5	O
region	O
of	O
bacterial	O
16S	O
rRNA	O
gene	O
was	O
performed	O
.	O

Results	O

We	O
obtained	O
138	O
,	O
218	O
high	O
quality	O
sequences	O
which	O
were	O
rarefied	O
at	O
133	O
sequences	O
/	O
sample	O
.	O

Twenty	O
OTUs	O
had	O
sequences	O
≥	O
1	O
%	O
of	O
total	O
.	O

There	O
were	O
marked	O
differences	O
in	O
the	O
distribution	O
of	O
Phyla	O
between	O
groups	O
(	O
P	O
=	O
2	O
.	O
8x10	O
-	O
118	O
).	O

Bacteroidetes	B-OG
and	O
Fusobacteria	B-OG
were	O
reduced	O
in	O
non	O
-	O
severe	O
and	O
severe	O
asthmatic	O
groups	O
.	O

Proteobacteria	B-OG
were	O
more	O
common	O
in	O
non	O
-	O
severe	O
asthmatics	O
compared	O
to	O
controls	O
(	O
OR	O
=	O
2	O
.	O
26	O
;	O
95	O
%	O
CI	O
=	O
1	O
.	O
94	O
–	O
2	O
.	O
64	O
)	O
and	O
Firmicutes	B-OG
were	O
increased	O
in	O
severe	O
asthmatics	O
compared	O
to	O
controls	O
(	O
OR	O
=	O
2	O
.	O
15	O
;	O
95	O
%	O
CI	O
=	O
1	O
.	O
89	O
–	O
2	O
.	O
45	O
).	O

Streptococcal	O
OTUs	O
amongst	O
the	O
Firmicutes	B-OG
were	O
associated	O
with	O
recent	O
onset	O
asthma	B-DS
,	O
rhinosinusitis	B-DS
and	O
sputum	O
eosinophilia	B-DS
.	O

Conclusions	O

Sputum	O
microbiota	B-OG
in	O
severe	O
asthma	B-DS
differs	O
from	O
healthy	O
controls	O
and	O
non	O
-	O
severe	O
asthmatics	O
,	O
and	O
is	O
characterized	O
by	O
the	O
presence	O
of	O
Streptococcus	B-OG
spp	I-OG
with	O
eosinophilia	B-DS
.	O

Whether	O
these	O
organisms	O
are	O
causative	O
for	O
the	O
pathophysiology	O
of	O
asthma	B-DS
remains	O
to	O
be	O
determined	O
.	O

Introduction	O

Asthma	B-DS
is	O
a	O
common	O
airway	O
condition	O
characterized	O
by	O
airway	O
inflammation	O
and	O
intermittent	O
episodes	O
of	O
airflow	O
obstruction	O
.	O

That	O
asthma	B-DS
is	O
a	O
syndrome	O
consisting	O
of	O
different	O
phenotypes	O
has	O
been	O
recognised	O
for	O
a	O
long	O
time	O
by	O
clinicians	O
[	O
1	O
].	O

Features	O
such	O
as	O
the	O
onset	O
of	O
asthma	B-DS
either	O
in	O
childhood	O
or	O
during	O
later	O
years	O
,	O
the	O
presence	O
of	O
atopy	O
,	O
the	O
effect	O
of	O
upper	B-DS
respiratory	I-DS
tract	I-DS
viral	I-DS
infections	I-DS
in	O
inducing	O
exacerbations	O
of	O
asthma	B-DS
,	O
asthma	B-DS
induced	O
by	O
ingestion	O
of	O
aspirin	O
or	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
agents	O
,	O
and	O
the	O
concomitant	O
presence	O
of	O
comorbidities	O
such	O
as	O
rhinosinusitis	B-DS
or	O
obesity	B-DS
,	O
have	O
been	O
recognised	O
as	O
important	O
clinical	O
features	O
that	O
delineate	O
certain	O
asthma	B-DS
clusters	O
[	O
1	O
,	O
2	O
].	O

In	O
addition	O
,	O
asthma	B-DS
may	O
be	O
categorised	O
by	O
the	O
severity	O
of	O
chronic	O
symptoms	O
and	O
by	O
the	O
occurrence	O
of	O
recurrent	O
exacerbations	O
of	O
asthma	B-DS
despite	O
treatment	O
with	O
maximal	O
asthma	B-DS
medications	O
including	O
corticosteroids	O
[	O
3	O
].	O

T	O
-	O
helper	O
type	O
2	O
cells	O
[	O
Th2	O
]	O
are	O
recognised	O
as	O
an	O
important	O
underlying	O
mechanism	O
of	O
a	O
specific	O
asthma	B-DS
phenotype	O
that	O
is	O
associated	O
with	O
high	O
levels	O
of	O
circulating	O
IgE	B-GP
and	O
atopy	O
,	O
and	O
eosinophilia	B-DS
[	O
4	O
,	O
5	O
]	O
The	O
presence	O
of	O
eosinophils	O
in	O
sputum	O
samples	O
has	O
been	O
known	O
to	O
be	O
associated	O
with	O
asthma	B-DS
and	O
has	O
been	O
used	O
to	O
indicate	O
a	O
good	O
therapeutic	O
response	O
to	O
inhaled	O
or	O
oral	O
corticosteroid	O
therapy	O
[	O
6	O
,	O
7	O
].	O

On	O
the	O
other	O
hand	O
,	O
those	O
with	O
neutrophilic	O
inflammation	O
have	O
been	O
linked	O
to	O
corticosteroid	O
insensitivity	O
and	O
in	O
some	O
instances	O
to	O
bacterial	B-DS
infections	I-DS
and	O
colonisation	O
[	O
8	O
,	O
9	O
].	O

Consistent	O
epidemiological	O
indications	O
of	O
the	O
importance	O
of	O
the	O
microbiome	O
in	O
asthma	B-DS
include	O
the	O
protection	O
afforded	O
by	O
a	O
rich	O
microbial	O
environment	O
in	O
early	O
life	O
[	O
10	O
,	O
11	O
],	O
observations	O
that	O
the	O
bronchial	O
tree	O
contains	O
a	O
characteristic	O
flora	O
that	O
is	O
disturbed	O
by	O
the	O
presence	O
of	O
pathogens	O
in	O
asthma	B-DS
[	O
12	O
–	O
14	O
],	O
birth	O
cohort	O
studies	O
showing	O
that	O
the	O
presence	O
of	O
the	O
same	O
pathogens	O
in	O
throat	O
swabs	O
predicts	O
the	O
later	O
development	O
of	O
asthma	B-DS
[	O
15	O
],	O
recognition	O
that	O
these	O
bacteria	B-OG
have	O
consistently	O
been	O
associated	O
with	O
exacerbations	O
of	O
asthma	B-DS
[	O
16	O
],	O
and	O
evidence	O
for	O
the	O
efficacy	O
of	O
antibiotics	O
in	O
the	O
treatment	O
of	O
asthma	B-DS
and	O
related	O
syndromes	O
[	O
17	O
–	O
19	O
].	O

In	O
27	O
%	O
of	O
asthmatic	O
patients	O
presenting	O
with	O
an	O
exacerbation	O
of	O
asthma	B-DS
,	O
bacteria	B-OG
have	O
been	O
cultured	O
from	O
sputum	O
samples	O
,	O
with	O
Streptococcus	B-OG
pneumoniae	I-OG
,	O
Streptococcus	B-OG
pyogenes	I-OG
,	O
Staphylococcus	B-OG
aureus	I-OG
,	O
Moraxella	B-OG
catarrhalis	I-OG
and	O
Haemophilus	B-OG
influenzae	I-OG
being	O
the	O
most	O
frequent	O
bacteria	B-OG
isolated	O
[	O
20	O
].	O

This	O
spectrum	O
of	O
bacterial	O
species	O
was	O
also	O
isolated	O
from	O
induced	O
sputum	O
samples	O
in	O
15	O
%	O
of	O
patients	O
during	O
a	O
stable	O
period	O
of	O
asthma	B-DS
[	O
8	O
].	O

In	O
addition	O
,	O
other	O
species	O
such	O
as	O
Mycoplasma	B-OG
pneumoniae	I-OG
and	O
Chlamydophila	B-OG
pneumoniae	I-OG
have	O
also	O
been	O
detected	O
in	O
patients	O
with	O
asthma	B-DS
[	O
21	O
].	O

Using	O
a	O
terminal	O
restriction	O
fragment	O
length	O
polymorphism	O
profiling	O
for	O
bacterial	O
community	O
analysis	O
,	O
another	O
study	O
showed	O
that	O
the	O
dominant	O
species	O
within	O
the	O
airway	O
bacterial	O
community	O
in	O
sputum	O
samples	O
from	O
treatment	O
-	O
resistant	O
asthma	B-DS
was	O
Moraxella	B-OG
catarrhalis	I-OG
or	O
a	O
member	O
of	O
the	O
Haemophilus	B-OG
or	O
Streptococcus	B-OG
genera	O
[	O
22	O
].	O

16S	O
ribosomal	O
RNA	O
microarray	O
rather	O
than	O
conventional	O
culture	O
techniques	O
have	O
been	O
used	O
recently	O
to	O
detect	O
operational	O
taxonomic	O
units	O
in	O
lower	O
airway	O
epithelial	O
samples	O
.	O

This	O
technique	O
has	O
led	O
to	O
the	O
detection	O
of	O
a	O
microbiome	O
in	O
the	O
lower	O
airways	O
of	O
normal	O
subjects	O
that	O
has	O
hitherto	O
been	O
considered	O
to	O
be	O
a	O
sterile	O
environment	O
.	O

In	O
addition	O
,	O
airways	O
of	O
asthmatic	O
subjects	O
were	O
reported	O
to	O
show	O
a	O
different	O
microbiota	B-OG
compared	O
to	O
non	O
-	O
asthmatic	O
subjects	O
in	O
terms	O
of	O
an	O
increase	O
in	O
Proteobacteria	B-OG
particularly	O
in	O
Haemophilus	B-OG
,	O
Moraxella	B-OG
,	O
and	O
Neisseria	B-OG
spp	I-OG
,	O
with	O
a	O
reduction	O
in	O
Bacteroidetes	B-OG
[	O
12	O
].	O

Another	O
study	O
confirmed	O
the	O
increase	O
in	O
bacterial	O
load	O
particularly	O
Proteobacteria	B-OG
in	O
the	O
lower	O
airways	O
of	O
asthmatics	O
,	O
and	O
the	O
total	O
bacterial	O
burden	O
and	O
diversity	O
correlated	O
with	O
bronchial	B-DS
hyperresponsiveness	I-DS
[	O
13	O
].	O

In	O
induced	O
sputum	O
,	O
a	O
higher	O
proportion	O
of	O
Proteobacteria	B-OG
with	O
lesser	O
content	O
of	O
Firmicutes	B-OG
and	O
Actinobacteria	B-OG
in	O
asthmatics	O
compared	O
to	O
non	O
-	O
asthmatics	O
was	O
reported	O
.	O

By	O
contrast	O
,	O
no	O
differences	O
in	O
airway	O
bacterial	O
load	O
were	O
observed	O
between	O
subjects	O
with	O
asthma	B-DS
and	O
normal	O
control	O
subjects	O
as	O
assessed	O
by	O
16S	O
rRNA	O
copy	O
number	O
[	O
23	O
].	O

Neonates	O
colonized	O
in	O
the	O
hypopharyngeal	O
region	O
with	O
S	B-OG
.	I-OG
pneumoniae	I-OG
,	O
H	B-OG
.	I-OG
influenzae	I-OG
or	O
M	B-OG
.	I-OG
catarrhalis	I-OG
,	O
or	O
with	O
a	O
combination	O
of	O
these	O
organisms	O
were	O
at	O
increased	O
risk	O
for	O
recurrent	O
wheeze	O
and	O
asthma	B-DS
early	O
in	O
life	O
[	O
15	O
].	O

In	O
neonates	O
from	O
the	O
tropics	O
,	O
the	O
increased	O
prevalence	O
of	O
Haemophilus	B-OG
and	O
Staphylococcus	B-OG
spp	I-OG
was	O
proposed	O
to	O
contribute	O
to	O
wheezing	O
illnesses	O
[	O
14	O
].	O

Whether	O
they	O
contribute	O
to	O
asthma	B-DS
pathogenesis	O
or	O
whether	O
they	O
are	O
altered	O
as	O
a	O
consequence	O
of	O
asthma	B-DS
is	O
at	O
present	O
unresolved	O
[	O
24	O
].	O

However	O
,	O
the	O
role	O
of	O
pathogens	O
in	O
causing	O
disease	O
and	O
the	O
actions	O
of	O
commensal	O
bacteria	B-OG
in	O
maintaining	O
a	O
healthy	O
mucosa	O
in	O
the	O
gut	O
are	O
well	O
-	O
recognised	O
[	O
25	O
].	O

Previous	O
studies	O
of	O
the	O
airway	O
microbiome	O
showed	O
that	O
that	O
the	O
airways	O
of	O
moderate	O
asthmatics	O
contained	O
an	O
excess	O
of	O
Proteobacteria	B-OG
[	O
12	O
,	O
26	O
]	O
compared	O
to	O
normal	O
controls	O
,	O
but	O
asthma	B-DS
is	O
heterogeneous	O
in	O
its	O
clinical	O
presentation	O
and	O
severity	O
[	O
3	O
,	O
27	O
]	O
and	O
it	O
is	O
possible	O
that	O
the	O
airways	O
of	O
severe	O
asthmatics	O
have	O
a	O
different	O
microbiota	B-OG
.	O

In	O
stable	O
asthma	B-DS
patients	O
with	O
more	O
severe	O
disease	O
,	O
up	O
to	O
half	O
had	O
one	O
or	O
more	O
bacteria	B-OG
cultured	O
from	O
sputum	O
,	O
with	O
H	B-OG
.	I-OG
influenzae	I-OG
,	O
P	B-OG
.	I-OG
aeruginosa	I-OG
and	O
S	B-OG
.	I-OG
aureus	I-OG
being	O
the	O
most	O
common	O
[	O
28	O
].	O

It	O
is	O
therefore	O
extremely	O
valid	O
and	O
important	O
to	O
examine	O
the	O
respiratory	O
microbiota	B-OG
in	O
patients	O
with	O
severe	O
asthma	B-DS
and	O
determine	O
whether	O
the	O
airway	O
microbiota	B-OG
is	O
altered	O
compared	O
to	O
mild	O
-	O
moderate	O
asthma	B-DS
as	O
these	O
differences	O
could	O
be	O
important	O
in	O
determining	O
both	O
the	O
pathophysiology	O
and	O
treatment	O
of	O
severe	O
asthma	B-DS
.	O

Therefore	O
,	O
we	O
have	O
determined	O
whether	O
patients	O
with	O
severe	O
asthma	B-DS
have	O
an	O
altered	O
microbiota	B-OG
compared	O
to	O
non	O
-	O
severe	O
asthma	B-DS
measured	O
by	O
high	O
throughput	O
sequencing	O
of	O
16S	O
ribosomal	O
RNA	O
gene	O
.	O

More	O
importantly	O
,	O
we	O
also	O
determined	O
whether	O
the	O
altered	O
microbiota	B-OG
were	O
associated	O
with	O
any	O
particular	O
phenotype	O
of	O
asthma	B-DS
.	O

Methods	O

This	O
study	O
was	O
approved	O
by	O
the	O
Ethics	O
Committee	O
of	O
the	O
Royal	O
Brompton	O
&	O
Harefield	O
NHS	O
Trust	O
.	O

All	O
patients	O
provided	O
written	O
informed	O
consent	O
to	O
participate	O
in	O
this	O
study	O
by	O
signing	O
the	O
consent	O
form	O
that	O
was	O
approved	O
by	O
the	O
Ethics	O
Committee	O
of	O
the	O
Royal	O
Brompton	O
&	O
Harefield	O
NHS	O
Trust	O
.	O

Subjects	O

All	O
non	O
-	O
asthmatic	O
subjects	O
were	O
healthy	O
volunteers	O
without	O
any	O
disease	O
with	O
normal	O
spirometric	O
results	O
(	O
Table	O
1	O
).	O

Patients	O
with	O
severe	O
asthma	B-DS
were	O
recruited	O
from	O
the	O
Severe	O
Asthma	B-DS
clinic	O
at	O
the	O
Royal	O
Brompton	O
Hospital	O
,	O
London	O
,	O
over	O
a	O
6	O
-	O
month	O
period	O
.	O

Patients	O
with	O
severe	O
asthma	B-DS
needed	O
either	O
continuous	O
or	O
near	O
-	O
continuous	O
oral	O
corticosteroids	O
,	O
high	O
-	O
dose	O
inhaled	O
corticosteroids	O
,	O
or	O
both	O
to	O
achieve	O
a	O
level	O
of	O
mild	O
-	O
to	O
-	O
moderate	B-DS
persistent	I-DS
asthma	I-DS
,	O
and	O
by	O
2	O
or	O
more	O
minor	O
criteria	O
[	O
29	O
].	O

All	O
patients	O
had	O
been	O
attending	O
the	O
clinic	O
for	O
at	O
least	O
6	O
months	O
and	O
had	O
undergone	O
a	O
Severe	O
Asthma	B-DS
Protocol	O
for	O
confirmation	O
of	O
the	O
diagnosis	O
of	O
severe	O
asthma	B-DS
[	O
30	O
].	O

Patients	O
with	O
non	O
-	O
severe	O
asthma	B-DS
had	O
controlled	O
asthma	B-DS
as	O
defined	O
by	O
no	O
daytime	O
or	O
nocturnal	O
symptoms	O
,	O
no	O
limitation	O
of	O
activities	O
,	O
minimal	O
use	O
of	O
rescue	O
medication	O
while	O
using	O
up	O
to	O
2	O
,	O
000	O
μg	O
/	O
d	O
or	O
equivalent	O
of	O
inhaled	O
beclomethasone	O
.	O

Current	O
smokers	O
and	O
ex	O
-	O
smokers	O
of	O
greater	O
than	O
5	O
pack	O
years	O
were	O
excluded	O
.	O

Patients	O
with	O
an	O
exacerbation	O
of	O
asthma	B-DS
within	O
the	O
last	O
4	O
weeks	O
or	O
with	O
a	O
respiratory	B-DS
tract	I-DS
infection	I-DS
requiring	O
antibiotic	O
treatment	O
within	O
6	O
weeks	O
were	O
excluded	O
.	O

Characteristics	O
of	O
the	O
subjects1	O
.	O

Parameters	O

Healthy	O

Non	O
-	O
severe	O
asthma	B-DS

Severe	O
asthma	B-DS

Number	O

12	O

18	O

26	O

Age	O
(	O
years	O
)	O

35	O
.	O
4	O
±	O
10	O
.	O
3	O

45	O
.	O
2	O
±	O
16	O
.	O
0	O

47	O
.	O
9	O
±	O
10	O
.	O
9	O
**	O

Gender	O
(	O
male	O
:	O
female	O
)	O

1	O
:	O
11	O

10	O
:	O
8	O

9	O
:	O
17	O

BMI	O
(	O
kg	O
/	O
m2	O
)	O

24	O
.	O
5	O
±	O
5	O
.	O
7	O

26	O
.	O
9	O
±	O
4	O
.	O
7	O

28	O
.	O
9	O
±	O
6	O
.	O
2	O
*	O

Duration	O
of	O
asthma	B-DS
(	O
years	O
)	O

0	O

29	O
.	O
7	O
±	O
19	O
.	O
3	O

22	O
.	O
6	O
±	O
16	O
.	O
5	O

Ex	O
-	O
Smoker	O
(	O
n	O
)	O

0	O

3	O

0	O

Rhinosinusitis	B-DS
(	O
n	O
)	O

0	O

4	O

8	O

Atopy	O
4	O
(	O
n	O
)	O

0	O

9	O

24	O

IgE	B-GP
IU	O
/	O
L2	O

48	O
.	O
4	O
(	O
26	O
–	O
80	O
)	O

112	O
.	O
2	O
(	O
14	O
–	O
510	O
)**	O

148	O
.	O
4	O
(	O
2	O
–	O
4335	O
)**	O
¶	O

Daily	O
prednisolone	O
(	O
mg	O
.	O
day	O
-	O
1	O
)	O

0	O

0	O

17	O
.	O
5	O
±	O
9	O
.	O
3	O

Inhaled	O
corticosteroids3	O
(	O
μg	O
.	O
day	O
-	O
1	O
)	O

0	O

1453	O
±	O
563	O

2348	O
±	O
1140	O
¶¶	O

FEV1	O
(	O
L	O
)	O

3	O
.	O
78	O
±	O
0	O
.	O
63	O

2	O
.	O
88	O
±	O
0	O
.	O
94	O

2	O
.	O
25	O
±	O
0	O
.	O
60	O

FEV1	O
(%	O
predicted	O
)	O

98	O
.	O
7	O
±	O
11	O
.	O
0	O

87	O
.	O
0	O
±	O
15	O
.	O
3	O

76	O
.	O
7	O
±	O
15	O
.	O
9	O

FVC	O
(	O
L	O
)	O

4	O
.	O
69	O
±	O
0	O
.	O
59	O

3	O
.	O
89	O
±	O
0	O
.	O
98	O

3	O
.	O
25	O
±	O
0	O
.	O
74	O

FVC	O
(%	O
predicted	O
)	O

101	O
.	O
8	O
±	O
6	O
.	O
3	O

99	O
.	O
8	O
±	O
14	O
.	O
7	O

92	O
.	O
0	O
±	O
11	O
.	O
7	O

Bronchodilator	O
reversibility5	O
(%)	O

Not	O
done	O

14	O
.	O
4	O
±	O
10	O
.	O
0	O

17	O
.	O
9	O
±	O
12	O
.	O
1	O

Blood	O
eosinophils	O
(	O
per	O
μl	O
)	O

0	O
.	O
10	O
±	O
0	O
.	O
0	O

0	O
.	O
28	O
±	O
0	O
.	O
17	O
**	O

0	O
.	O
40	O
±	O
0	O
.	O
51	O

Sputum	O
eosinophils	O
(%)	O

0	O
.	O
4	O
±	O
0	O
.	O
4	O

6	O
.	O
9	O
±	O
12	O
.	O
4	O

19	O
.	O
4	O
±	O
26	O
.	O
9	O
**	O
¶	O

Sputum	O
neutrophils	O
(%)	O

49	O
.	O
6	O
±	O
27	O
.	O
6	O

45	O
.	O
7	O
±	O
24	O
.	O
8	O

45	O
.	O
0	O
±	O
27	O
.	O
4	O

1	O
Data	O
shown	O
as	O
mean	O
±	O
SD	O
unless	O
otherwise	O
denoted	O
.	O

2	O
Data	O
shown	O
as	O
geometric	O
mean	O
and	O
range	O
.	O

3	O
Inhaled	O
corticosteroid	O
expressed	O
as	O
beclomethasone	O
propionate	O
equivalent	O
dose	O

4	O
Atopy	O
defined	O
as	O
by	O
the	O
presence	O
of	O
positive	O
skin	O
-	O
prick	O
tests	O
to	O
at	O
least	O
one	O
common	O
aeroallergen	O
.	O

5	O
Bronchodilator	O
reversibility	O
calculated	O
as	O
postbronchodilator	O
FEV1	O
-	O
prebronchodilator	O
FEV1	O
/	O
prebronchodilator	O
FEV1	O
x	O
100	O
.	O

BMI	O
:	O
Body	O
mass	O
index	O
;	O
FEV1	O
:	O
forced	O
expiratory	O
volume	O
in	O
one	O
second	O
;	O
FVC	O
:	O
forced	O
vital	O
capacity	O
.	O

*	O
P	O
<	O
0	O
.	O
05	O
compared	O
to	O
healthy	O
controls	O
;	O

**	O
P	O
<	O
0	O
.	O
01	O
compared	O
to	O
healthy	O
controls	O
;	O

¶	O
P	O
<	O
0	O
.	O
05	O
compared	O
to	O
non	O
-	O
severe	O
asthma	B-DS
;	O

¶¶	O
P	O
<	O
0	O
.	O
01	O
compared	O
to	O
non	O
-	O
severe	O
asthma	B-DS
.	O

Lung	O
function	O
and	O
atopic	O
status	O

FEV1	O
and	O
forced	O
vital	O
capacity	O
(	O
FVC	O
)	O
were	O
measured	O
using	O
a	O
spirometer	O
(	O
Erich	O
Jaeger	O
UK	O
Ltd	O
,	O
Market	O
Harborough	O
,	O
UK	O
).	O

Atopy	O
was	O
defined	O
by	O
the	O
presence	O
of	O
positive	O
skin	O
-	O
prick	O
tests	O
to	O
at	O
least	O
one	O
common	O
aeroallergen	O
including	O
house	B-OG
dust	I-OG
mite	I-OG
,	O
grass	O
and	O
tree	B-OG
pollen	O
,	O
cat	B-OG
dander	O
,	O
dog	B-OG
dander	O
and	O
Aspergillus	B-OG
.	O

Sputum	O
induction	O
,	O
cell	O
count	O
and	O
microbiology	O

Sputum	O
was	O
induced	O
by	O
inhalation	O
of	O
an	O
aerosol	O
of	O
sterile	O
3	O
%	O
saline	O
solution	O
and	O
subsequently	O
increasing	O
to	O
4	O
%	O
and	O
5	O
%	O
during	O
3	O
periods	O
of	O
2	O
minutes	O
each	O
after	O
the	O
subject	O
has	O
had	O
pre	O
-	O
treatment	O
with	O
inhaled	O
salbutamol	O
[	O
31	O
].	O

Particular	O
care	O
was	O
taken	O
to	O
avoid	O
contamination	O
with	O
saliva	O
and	O
post	O
-	O
nasal	O
drip	O
by	O
instructing	O
subjects	O
to	O
rinse	O
orally	O
with	O
water	O
and	O
to	O
blow	O
their	O
nose	O
after	O
each	O
inhalation	O
.	O

Sputum	O
samples	O
were	O
collected	O
into	O
sterile	O
pots	O
.	O

Peak	O
flow	O
measurements	O
were	O
made	O
after	O
each	O
inhalation	O
.	O

The	O
procedure	O
was	O
not	O
carried	O
out	O
if	O
the	O
subject	O
brought	O
up	O
spontaneously	O
sputum	O
and	O
if	O
the	O
baseline	O
post	O
-	O
bronchodilator	O
FEV1	O
was	O
less	O
than	O
60	O
%	O
predicted	O
or	O
less	O
than	O
1	O
.	O
0	O
litre	O
.	O

If	O
there	O
was	O
a	O
fall	O
in	O
peak	O
flow	O
of	O
20	O
%	O
or	O
more	O
or	O
if	O
symptoms	O
occurred	O
during	O
the	O
procedure	O
,	O
the	O
induction	O
was	O
stopped	O
.	O

For	O
sputum	O
bacteriological	O
culture	O
,	O
an	O
aliquot	O
of	O
induced	O
sputum	O
was	O
selected	O
using	O
a	O
positive	O
displacement	O
pipette	O
and	O
used	O
for	O
quantitative	O
bacteriological	O
culture	O
[	O
30	O
].	O

Sputum	O
plugs	O
were	O
selected	O
and	O
one	O
portion	O
was	O
used	O
to	O
perform	O
differential	O
cell	O
counts	O
.	O

To	O
perform	O
differential	O
cell	O
counts	O
,	O
di	O
-	O
thiothreitol	O
was	O
added	O
to	O
the	O
sputum	O
plug	O
and	O
mixed	O
vigorously	O
on	O
a	O
plate	O
shaker	O
to	O
solubilize	O
the	O
sputum	O
.	O

Cytospins	O
were	O
then	O
prepared	O
,	O
and	O
differential	O
cell	O
counts	O
obtained	O
.	O

For	O
sputum	O
16S	O
RNA	O
assay	O
,	O
sputum	O
plugs	O
weighing	O
more	O
than	O
0	O
.	O
1g	O
were	O
selected	O
and	O
placed	O
in	O
a	O
1	O
.	O
5	O
ml	O
sterile	O
polypropylene	O
centrifuge	O
tube	O
for	O
DNA	O
extraction	O
.	O

DNA	O
extraction	O
and	O
PCR	O
amplification	O
and	O
sequencing	O

DNA	O
extraction	O
was	O
performed	O
using	O
the	O
QIAmp	O
DNA	O
Mini	O
Kit	O
extraction	O
kit	O
,	O
modified	O
to	O
include	O
a	O
bead	O
-	O
beating	O
step	O
.	O

The	O
method	O
proceeded	O
as	O
per	O
manufacturer	O
’	O
s	O
instruction	O
until	O
the	O
end	O
of	O
the	O
Proteinase	B-GP
K	I-GP
incubation	O
,	O
when	O
the	O
sample	O
and	O
lysis	O
buffer	O
were	O
transferred	O
to	O
lysing	O
matrix	O
E	O
bead	O
-	O
beating	O
tubes	O
(	O
LME	O
tubes	O
;	O
MP	O
Biomedicals	O
),	O
and	O
beaten	O
in	O
a	O
Precellys	O
bead	O
-	O
beater	O
(	O
Bertin	O
Technologies	O
)	O
for	O
2	O
cycles	O
of	O
30	O
seconds	O
at	O
6800	O
rpm	O
.	O

DNA	O
was	O
eluted	O
from	O
the	O
QIAmp	O
columns	O
in	O
40	O
μl	O
of	O
nuclease	B-GP
free	O
water	O
and	O
stored	O
at	O
-	O
80	O
°	O
C	O
until	O
further	O
use	O
.	O

PCR	O
amplification	O
of	O
the	O
V3	O
-	O
V5	O
region	O
of	O
the	O
16S	O
rRNA	O
gene	O
was	O
performed	O
using	O
1	O
μl	O
of	O
extracted	O
DNA	O
template	O
.	O

Reactions	O
were	O
performed	O
in	O
quadruplicate	O
using	O
primer	O
pair	O
357F	O
/	O
926R	O
(	O
357F	O
-	O
CCTACGGGAGGCAGCAG	O
,	O
926R	O
-	O
CCGTCAATTCMTTTRAGT	O
),	O
coupled	O
with	O
Roche	O
454	O
sequencing	O
adaptors	O
A	O
(	O
reverse	O
primer	O
)	O
and	O
B	O
(	O
forward	O
primer	O
)	O
and	O
a	O
unique	O
12	O
base	O
-	O
pair	O
barcode	O
[	O
32	O
].	O

Replicates	O
were	O
combined	O
and	O
purified	O
twice	O
using	O
Ampure	O
XP	O
(	O
Beckman	O
Coulter	O
)	O
bead	O
purification	O
,	O
before	O
quantification	O
using	O
the	O
Quant	O
iT	O
kit	O
(	O
Life	O
Technologies	O
)	O
and	O
equimolar	O
pooling	O
.	O

Thirty	O
to	O
fifty	O
samples	O
were	O
pooled	O
in	O
each	O
sequencing	O
run	O
on	O
a	O
Roche	O
454	O
Junior	O
pyrosequencer	O
,	O
using	O
the	O
Lib	O
-	O
L	O
kit	O
and	O
protocol	O
(	O
Roche	O
Diagnostics	O
Ltd	O
).	O

Data	O
pre	O
-	O
processing	O

Raw	O
sequence	O
files	O
from	O
each	O
run	O
were	O
combined	O
prior	O
to	O
denoising	O
and	O
chimera	O
removal	O
in	O
QIIME	O
[	O
33	O
]	O
using	O
Ampliconnoise	O
and	O
Perseus	O
[	O
34	O
].	O

Operational	O
taxonomic	O
units	O
(	O
OTUs	O
)	O
at	O
97	O
%	O
identity	O
were	O
picked	O
using	O
UCLUST	O
[	O
35	O
],	O
the	O
most	O
abundant	O
sequences	O
in	O
each	O
OTU	O
selected	O
as	O
representatives	O
and	O
classified	O
using	O
the	O
RDP	O
classifier	O
[	O
36	O
]	O
retrained	O
with	O
the	O
Silva	O
database	O
version	O
111	O
[	O
37	O
].	O

Random	O
resampling	O
of	O
the	O
OTU	O
table	O
to	O
133	O
reads	O
was	O
performed	O
in	O
order	O
to	O
ensure	O
equal	O
sequence	O
depth	O
of	O
each	O
sample	O
,	O
whilst	O
maintaining	O
the	O
ability	O
to	O
discriminate	O
between	O
samples	O
,	O
resulting	O
in	O
3458	O
analysed	O
.	O

Data	O
analysis	O

Statistical	O
analyses	O
of	O
phenotypic	O
relationships	O
were	O
all	O
carried	O
out	O
using	O
IBM	O
SPSS	O
version	O
21	O
.	O

Asthma	B-DS
status	O
was	O
coded	O
as	O
non	O
-	O
asthmatic	O
=	O
0	O
,	O
non	O
-	O
severe	O
asthma	B-DS
=	O
1	O
,	O
and	O
severe	O
asthma	B-DS
=	O
2	O
.	O

The	O
complex	O
relationships	O
between	O
phenotypic	O
variables	O
were	O
explored	O
with	O
Principal	O
Components	O
Analysis	O
(	O
PCA	O
)	O
in	O
the	O
FACTOR	O
routine	O
in	O
SPSS	O
.	O

Missing	O
values	O
were	O
replaced	O
with	O
the	O
study	O
mean	O
for	O
the	O
relevant	O
parameter	O
.	O

PCs	O
with	O
an	O
eigenvalue	O
>	O
1	O
were	O
retained	O
in	O
the	O
analysis	O
,	O
and	O
a	O
varimax	O
rotation	O
was	O
applied	O
.	O

Bacterial	O
counts	O
were	O
log	O
-	O
normalised	O
after	O
adding	O
1	O
to	O
each	O
count	O
(	O
to	O
return	O
a	O
log	O
value	O
of	O
0	O
when	O
the	O
count	O
was	O
0	O
)	O
before	O
parametric	O
analyses	O
.	O

Analyses	O
of	O
community	O
diversity	O
were	O
carried	O
out	O
in	O
the	O
R	O
statistical	O
environment	O
using	O
the	O
Phyloseq	O
and	O
Vegan	O
packages	O
.	O

Results	O

Patient	O
characteristics	O

The	O
study	O
population	O
consisted	O
of	O
56	O
subjects	O
(	O
12	O
normal	O
subjects	O
,	O
18	O
non	O
-	O
severe	O
asthmatics	O
and	O
26	O
severe	O
asthmatics	O
)	O
(	O
Table	O
1	O
).	O

Severe	O
asthmatics	O
had	O
lower	O
%	O
FEV1	O
predicted	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
and	O
higher	O
sputum	O
eosinophil	O
counts	O
(	O
P	O
<	O
0	O
.	O
05	O
),	O
and	O
higher	O
BMI	O
and	O
atopy	O
compared	O
to	O
non	O
-	O
severe	O
asthma	B-DS
and	O
normal	O
subjects	O
.	O

15	O
of	O
the	O
26	O
severe	O
asthma	B-DS
patients	O
were	O
on	O
daily	O
oral	O
prednisolone	O
using	O
a	O
mean	O
dose	O
of	O
17	O
.	O
5	O
mg	O
per	O
day	O
.	O

Out	O
of	O
the	O
56	O
samples	O
,	O
potentially	O
pathogenic	O
bacteria	B-OG
were	O
cultured	O
from	O
the	O
sputum	O
of	O
5	O
stable	O
severe	O
asthmatics	O
(	O
3	O
x	O
Haemophilus	B-OG
influenzae	I-OG
,	O
1	O
x	O
Moraxella	B-OG
catarrhalis	I-OG
and	O
1	O
x	O
Staphylococcus	B-OG
aureus	I-OG
)	O
and	O
5	O
stable	O
non	O
-	O
severe	O
asthmatics	O
(	O
1x	O
,	O
2x	O
and	O
2x	O
respectively	O
).	O

No	O
potentially	O
pathogenic	O
bacteria	B-OG
were	O
cultured	O
from	O
the	O
12	O
healthy	O
controls	O
.	O

PCA	O
analysis	O
of	O
clinical	O
variables	O

PCA	O
was	O
carried	O
out	O
with	O
the	O
most	O
important	O
phenotypic	O
variables	O
(	O
Table	O
2	O
).	O

In	O
order	O
to	O
avoid	O
over	O
-	O
fitting	O
of	O
the	O
model	O
,	O
single	O
variables	O
were	O
chosen	O
to	O
represent	O
highly	O
correlated	O
related	O
parameters	O
.	O

Four	O
Principal	O
Components	O
(	O
PC1	O
-	O
4	O
)	O
with	O
eigenvalues	O
>	O
1	O
and	O
accounting	O
for	O
>	O
10	O
%	O
of	O
the	O
variance	O
were	O
identified	O
(	O
Table	O
2	O
).	O

Asthma	B-DS
status	O
(	O
from	O
normal	O
to	O
severe	O
asthma	B-DS
)	O
was	O
most	O
strongly	O
associated	O
with	O
the	O
first	O
two	O
PCs	O
,	O
PC1	O
and	O
PC2	O
(	O
Table	O
2	O
).	O

Principal	O
Components	O
Analysis	O
of	O
phenotypic	O
variables	O
.	O

Component	O
(%	O
of	O
total	O
variance	O
)	O

1	O
(	O
24	O
%)	O

2	O
(	O
16	O
%)	O

3	O
(	O
15	O
%)	O

4	O
(	O
12	O
%)	O

Diagnosis	O

0	O
.	O
663	O

0	O
.	O
525	O

0	O
.	O
191	O

0	O
.	O
273	O

FEV1	O
(%	O
predicted	O
)	O

-	O
0	O
.	O
117	O

-	O
0	O
.	O
515	O

-	O
0	O
.	O
227	O

-	O
0	O
.	O
520	O

Asthma	B-DS
duration	O

0	O
.	O
526	O

-	O
0	O
.	O
113	O

0	O
.	O
567	O

Atopic	O
status	O

0	O
.	O
773	O

0	O
.	O
351	O

0	O
.	O
213	O

Rhinosinusitis	B-DS

0	O
.	O
138	O

0	O
.	O
619	O

0	O
.	O
271	O

Body	O
mass	O
index	O

0	O
.	O
525	O

Age	O

0	O
.	O
139	O

0	O
.	O
149	O

0	O
.	O
802	O

Inhaled	O
corticosteroids	O

0	O
.	O
860	O

0	O
.	O
101	O

0	O
.	O
318	O

Salbutamol	O
use	O

0	O
.	O
379	O

0	O
.	O
671	O

-	O
0	O
.	O
174	O

Long	O
-	O
acting	O
β	O
-	O
agonist	O

0	O
.	O
836	O

0	O
.	O
118	O

0	O
.	O
364	O

Oral	O
corticosteroids	O

0	O
.	O
202	O

0	O
.	O
895	O

Sputum	O
neutrophils	O

-	O
0	O
.	O
750	O

0	O
.	O
247	O

Sputum	O
eosinophils	O

-	O
0	O
.	O
188	O

0	O
.	O
532	O

0	O
.	O
602	O

0	O
.	O
215	O

Blood	O
eosinophils	O

-	O
0	O
.	O
105	O

0	O
.	O
773	O

0	O
.	O
127	O

Principal	O
Components	O
accounting	O
for	O
<	O
10	O
%	O
variance	O
and	O
vector	O
coefficients	O
<	O
0	O
.	O
1	O
are	O
not	O
shown	O
.	O

PC1	O
was	O
typified	O
by	O
asthma	B-DS
of	O
relatively	O
long	O
duration	O
,	O
atopy	O
,	O
a	O
relatively	O
high	O
BMI	O
,	O
the	O
use	O
of	O
inhaled	O
steroids	O
and	O
long	O
-	O
acting	O
β	O
-	O
agonist	O
and	O
a	O
weak	O
negative	O
association	O
with	O
%	O
sputum	O
eosinophils	O
.	O

PC2	O
was	O
associated	O
with	O
poor	O
lung	O
function	O
,	O
oral	O
corticosteroid	O
use	O
and	O
sputum	O
eosinophilia	B-DS
.	O

PC3	O
was	O
typified	O
by	O
relatively	O
recent	O
onset	O
,	O
nasal	B-DS
disease	I-DS
,	O
blood	O
and	O
sputum	O
eosinophilia	B-DS
,	O
and	O
relatively	O
fewer	O
neutrophils	O
in	O
sputum	O
.	O

PC4	O
was	O
characterised	O
by	O
the	O
relatively	O
increased	O
age	O
of	O
the	O
patients	O
,	O
poorer	O
lung	O
function	O
and	O
treatment	O
with	O
inhaled	O
corticosteroids	O
and	O
long	O
-	O
acting	O
β	O
-	O
agonist	O
.	O

Operational	O
taxonomic	O
units	O
(	O
OTUs	O
)	O

We	O
obtained	O
a	O
total	O
of	O
138	O
,	O
218	O
high	O
quality	O
sequences	O
after	O
de	O
-	O
noising	O
and	O
chimera	O
removal	O
.	O

Following	O
exclusion	O
of	O
singletons	O
,	O
163	O
OTUs	O
remained	O
.	O

Samples	O
were	O
rarefied	O
at	O
133	O
sequences	O
per	O
sample	O
for	O
statistical	O
analyses	O
,	O
such	O
that	O
a	O
total	O
of	O
7448	O
reads	O
were	O
used	O
for	O
subsequent	O
analyses	O
.	O

Rarefaction	O
with	O
higher	O
numbers	O
of	O
sequences	O
reduced	O
the	O
numbers	O
of	O
subjects	O
but	O
did	O
not	O
change	O
the	O
principal	O
findings	O
of	O
the	O
study	O
.	O

Many	O
of	O
the	O
OTUs	O
were	O
relatively	O
uncommon	O
,	O
and	O
we	O
found	O
31	O
OTUs	O
with	O
numbers	O
of	O
sequences	O
that	O
were	O
≥	O
0	O
.	O
5	O
%	O
of	O
the	O
total	O
,	O
20	O
OTUs	O
with	O
sequences	O
≥	O
1	O
%	O
of	O
the	O
total	O
and	O
10	O
OTUs	O
which	O
made	O
up	O
≥	O
2	O
%	O
of	O
the	O
total	O
.	O

Because	O
statistical	O
power	O
to	O
detect	O
associations	O
to	O
uncommon	O
OTUs	O
is	O
limited	O
,	O
we	O
confined	O
downstream	O
analyses	O
to	O
the	O
20	O
OTUs	O
with	O
sequences	O
≥	O
1	O
%	O
of	O
the	O
total	O
.	O

We	O
further	O
excluded	O
an	O
OTU	O
identified	O
as	O
Burkholderia	B-OG
(	O
1	O
.	O
3	O
%	O
of	O
total	O
reads	O
)	O
because	O
it	O
was	O
confined	O
to	O
three	O
subjects	O
and	O
our	O
kit	O
controls	O
indicated	O
it	O
to	O
be	O
a	O
common	O
contaminant	O
.	O

The	O
most	O
common	O
phylum	O
in	O
the	O
dataset	O
was	O
Firmicutes	B-OG
,	O
containing	O
35	O
.	O
4	O
%	O
of	O
sequences	O
,	O
followed	O
by	O
Bacteroidetes	B-OG
with	O
27	O
.	O
5	O
%	O
and	O
Proteobacteria	B-OG
with	O
24	O
.	O
5	O
%.	O

There	O
were	O
marked	O
differences	O
in	O
the	O
distribution	O
of	O
Phyla	O
between	O
the	O
three	O
patient	O
groups	O
(	O
χ2	O
=	O
530	O
,	O
5	O
d	O
.	O
f	O
.;	O
P	O
=	O
2	O
.	O
2x10	O
-	O
112	O
)	O
(	O
Fig	O
1	O
).	O

Distribution	O
of	O
bacterial	O
Phyla	O
in	O
healthy	O
controls	O
and	O
non	O
-	O
severe	O
and	O
severe	O
asthmatics	O
defined	O
by	O
sequencing	O
of	O
the	O
16S	O
rRNA	O
gene	O
.	O

The	O
distribution	O
of	O
bacterial	O
phyla	O
from	O
12	O
healthy	O
subjects	O
,	O
18	O
non	O
-	O
severe	O
asthmatics	O
and	O
26	O
severe	O
asthmatics	O
are	O
shown	O
.	O

Compared	O
to	O
healthy	O
controls	O
,	O
non	O
-	O
severe	O
asthmatics	O
showed	O
a	O
reduction	O
in	O
the	O
prevalence	O
of	O
Bacteroidetes	B-OG
and	O
Fusobacteria	B-OG
and	O
an	O
increase	O
in	O
Proteobacteria	B-OG
(	O
all	O
P	O
<	O
10	O
−	O
10	O
).	O

Severe	O
asthmatics	O
showed	O
an	O
increase	O
in	O
Firmicutes	B-OG
compared	O
to	O
controls	O
and	O
non	O
-	O
severe	O
asthmatics	O
,	O
together	O
with	O
reduction	O
in	O
Bacteroidetes	B-OG
and	O
Fusobacteria	B-OG
compared	O
to	O
controls	O
(	O
all	O
P	O
<	O
10	O
−	O
10	O
).	O

The	O
distribution	O
of	O
bacterial	O
phyla	O
is	O
given	O
in	O
the	O
accompanying	O
lower	O
Table	O
as	O
Operational	O
Taxonomic	O
Unit	O
(	O
OTU	O
)	O
counts	O
with	O
%	O
total	O
in	O
brackets	O
.	O

The	O
legend	O
gives	O
the	O
odds	O
ratios	O
for	O
each	O
comparison	O
.	O

The	O
overall	O
χ2	O
for	O
differences	O
in	O
phyla	O
between	O
phenotypic	O
groups	O
=	O
557	O
.	O
7	O
(	O
P	O
=	O
2	O
.	O
8x10	O
-	O
118	O
).	O
*	O
OUT	O
counts	O
(%	O
total	O
).	O

Comparison	O
between	O
healthy	O
controls	O
and	O
patients	O
with	O
non	O
-	O
severe	O
asthma	B-DS
showed	O
a	O
reduction	O
in	O
the	O
prevalence	O
of	O
Bacteroidetes	B-OG
,	O
containing	O
OTUs	O
identified	O
predominately	O
as	O
Gram	B-OG
-	I-OG
negative	I-OG
anaerobes	I-OG
such	O
as	O
Prevotella	B-OG
spp	I-OG
.	O

(	O
Odds	O
Ratio	O
(	O
OR	O
)	O
=	O
0	O
.	O
62	O
;	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
=	O
0	O
.	O
54	O
–	O
0	O
.	O
71	O
)	O
and	O
Fusobacteria	B-OG
(	O
OR	O
=	O
0	O
.	O
50	O
;	O
95	O
%	O
CI	O
=	O
0	O
.	O
40	O
–	O
0	O
.	O
63	O
)	O
(	O
Fig	O
1	O
),	O
whereas	O
Proteobacteria	B-OG
,	O
containing	O
potential	O
respiratory	O
pathogens	O
such	O
as	O
,	O
Neisseria	B-OG
and	O
Moraxella	B-OG
spp	I-OG
.,	O
were	O
more	O
common	O
in	O
the	O
patients	O
with	O
non	O
-	O
severe	O
asthma	B-DS
compared	O
to	O
controls	O
(	O
OR	O
=	O
2	O
.	O
26	O
;	O
95	O
%	O
CI	O
=	O
1	O
.	O
94	O
–	O
2	O
.	O
64	O
).	O

Bacteroidetes	B-OG
and	O
Fusobacteria	B-OG
were	O
also	O
reduced	O
in	O
the	O
severe	O
asthma	B-DS
group	O
compared	O
to	O
healthy	O
controls	O
(	O
OR	O
=	O
0	O
.	O
62	O
;	O
95	O
%	O
CI	O
=	O
0	O
.	O
54	O
–	O
0	O
.	O
70	O
and	O
OR	O
=	O
0	O
.	O
38	O
;	O
95	O
%	O
CI	O
=	O
0	O
.	O
31	O
–	O
0	O
.	O
48	O
,	O
respectively	O
)	O
(	O
Fig	O
1	O
).	O

A	O
minor	O
increase	O
in	O
Proteobacteria	B-OG
was	O
also	O
seen	O
in	O
the	O
severe	O
asthmatics	O
(	O
OR	O
=	O
1	O
.	O
21	O
;	O
95	O
%	O
CI	O
=	O
1	O
.	O
03	O
–	O
1	O
.	O
40	O
)	O
compared	O
to	O
non	O
-	O
asthmatic	O
controls	O
,	O
but	O
this	O
was	O
much	O
less	O
striking	O
than	O
the	O
increase	O
observed	O
in	O
Firmicutes	B-OG
,	O
consisting	O
predominately	O
of	O
streptococcal	O
OTUs	O
(	O
OR	O
=	O
2	O
.	O
15	O
;	O
95	O
%	O
CI	O
=	O
1	O
.	O
89	O
–	O
2	O
.	O
45	O
).	O

The	O
increased	O
presence	O
of	O
Firmicutes	B-OG
in	O
severe	O
asthma	B-DS
was	O
also	O
evident	O
in	O
comparison	O
with	O
the	O
non	O
-	O
severe	O
asthma	B-DS
group	O
(	O
OR	O
=	O
2	O
.	O
15	O
;	O
95	O
%	O
CI	O
=	O
1	O
.	O
92	O
–	O
2	O
.	O
41	O
)	O
(	O
Fig	O
1	O
).	O

These	O
results	O
are	O
consistent	O
with	O
earlier	O
studies	O
that	O
show	O
a	O
reduction	O
in	O
Bacteroidetes	B-OG
and	O
an	O
increase	O
in	O
Proteobacteria	B-OG
in	O
adults	O
and	O
children	O
with	O
asthma	B-DS
[	O
12	O
,	O
14	O
].	O

Our	O
present	O
results	O
also	O
indicate	O
that	O
the	O
microbiota	B-OG
of	O
severe	O
asthmatics	O
differs	O
from	O
that	O
of	O
non	O
-	O
severe	O
asthmatics	O
,	O
and	O
is	O
characterized	O
by	O
an	O
increase	O
in	O
the	O
prevalence	O
of	O
Firmicutes	B-OG
rather	O
than	O
Proteobacteria	B-OG
.	O

We	O
next	O
looked	O
for	O
differences	O
closer	O
to	O
the	O
species	O
level	O
,	O
defined	O
by	O
particular	O
OTUs	O
.	O

These	O
two	O
Streptococcus	B-OG
OTUs	O
were	O
positively	O
correlated	O
with	O
asthma	B-DS
severity	O
(	O
Streptococcus_23	O
,	O
r	O
=	O
0	O
.	O
41	O
,	O
P	O
=	O
0	O
.	O
002	O
;	O
and	O
Streptococcus_15	O
,	O
r	O
=	O
0	O
.	O
35	O
,	O
P	O
=	O
0	O
.	O
009	O
),	O
and	O
one	O
Prevotella	B-OG
OTU	O
showed	O
a	O
negative	O
correlation	O
(	O
Prevotella_292	O
,	O
r	O
=	O
0	O
.	O
36	O
,	O
P	O
=	O
0	O
.	O
007	O
).	O

Phylogenetic	O
analysis	O
of	O
these	O
sequences	O
was	O
not	O
able	O
to	O
further	O
differentiate	O
the	O
Streptococcus	B-OG
OTUs	O
into	O
individual	O
species	O
.	O
Fig	O
2	O
shows	O
the	O
heat	O
map	O
of	O
OTUs	O
found	O
in	O
the	O
sputum	O
samples	O
from	O
asthmatic	O
and	O
non	O
-	O
asthmatic	O
subjects	O
.	O

Heat	O
map	O
of	O
operational	O
taxonomic	O
units	O
(	O
OTUs	O
)	O
found	O
in	O
the	O
sputum	O
of	O
asthmatics	O
and	O
non	O
-	O
asthmatic	O
subjects	O
.	O

The	O
phylogenetic	O
tree	O
for	O
the	O
principal	O
(>	O
1	O
%	O
of	O
total	O
)	O
OTUs	O
is	O
shown	O
at	O
the	O
left	O
.	O

On	O
the	O
right	O
,	O
increasing	O
depth	O
of	O
colour	O
indicates	O
relative	O
abundance	O
of	O
the	O
OTU	O
in	O
an	O
individual	O
sample	O
.	O

Major	O
phyla	O
are	O
shown	O
between	O
the	O
phylogenetic	O
tree	O
and	O
the	O
heat	O
map	O
.	O

Proteo	B-OG
=	O
Proteobacteria	B-OG
;	O
Fuso	B-OG
=	O
Fusobacteria	B-OG
.	O

Repeating	O
the	O
PCA	O
and	O
including	O
the	O
individual	O
counts	O
for	O
these	O
three	O
OTUs	O
showed	O
that	O
PC3	O
(	O
relatively	O
recent	O
onset	O
asthma	B-DS
with	O
eosinophilia	B-DS
and	O
nasal	B-DS
disease	I-DS
)	O
was	O
most	O
strongly	O
related	O
with	O
the	O
presence	O
of	O
the	O
two	O
Streptococcus	B-OG
OTUs	O
(	O
Table	O
3	O
).	O

Weaker	O
relationships	O
were	O
seen	O
between	O
Streptococcus_23	O
and	O
PC1	O
(	O
atopic	O
disease	O
treated	O
with	O
inhaled	O
corticosteroid	O
and	O
long	O
-	O
acting	O
β	O
-	O
agonist	O
),	O
and	O
Streptococcus_155	O
and	O
PC2	O
(	O
severe	O
asthma	B-DS
with	O
sputum	O
eosinophilia	B-DS
).	O

PC2	O
was	O
also	O
associated	O
with	O
lower	O
counts	O
of	O
Prevotella_292	O
.	O

Principal	O
Components	O
Analysis	O
of	O
phenotypic	O
variables	O
including	O
microbial	O
associations	O
.	O

Component	O
(%	O
of	O
total	O
variance	O
)	O

1	O
(	O
21	O
%)	O

2	O
(	O
15	O
%)	O

3	O
(	O
13	O
%)	O

4	O
(	O
12	O
%)	O

Diagnosis	O

0	O
.	O
661	O

0	O
.	O
533	O

0	O
.	O
259	O

0	O
.	O
239	O

FEV1	O
(%	O
predicted	O
)	O

-	O
0	O
.	O
157	O

-	O
0	O
.	O
471	O

-	O
0	O
.	O
624	O

Asthma	B-DS
duration	O

0	O
.	O
668	O

-	O
0	O
.	O
237	O

0	O
.	O
319	O

Atopic	O
status	O

0	O
.	O
577	O

0	O
.	O
449	O

0	O
.	O
262	O

Rhinosinusitis	B-DS

0	O
.	O
111	O

0	O
.	O
311	O

0	O
.	O
595	O

Body	O
mass	O
index	O

0	O
.	O
225	O

0	O
.	O
289	O

0	O
.	O
102	O

Age	O

0	O
.	O
388	O

0	O
.	O
661	O

Inhaled	O
corticosteroids	O

0	O
.	O
934	O

0	O
.	O
173	O

Salbutamol	O
use	O

0	O
.	O
362	O

0	O
.	O
693	O

-	O
0	O
.	O
111	O

Long	O
-	O
acting	O
β	O
-	O
agonist	O

0	O
.	O
923	O

0	O
.	O
175	O

Oral	O
corticosteroids	O

0	O
.	O
897	O

0	O
.	O
207	O

Sputum	O
neutrophils	O

0	O
.	O
176	O

-	O
0	O
.	O
659	O

-	O
0	O
.	O
243	O

Sputum	O
eosinophils	O

-	O
0	O
.	O
134	O

0	O
.	O
326	O

0	O
.	O
471	O

0	O
.	O
525	O

Blood	O
eosinophils	O

0	O
.	O
558	O

0	O
.	O
487	O

Streptococcus_155	O

0	O
.	O
106	O

0	O
.	O
334	O

0	O
.	O
707	O

Streptococcus_23	O

0	O
.	O
342	O

0	O
.	O
671	O

Prevotella_292	O

-	O
0	O
.	O
120	O

-	O
0	O
.	O
404	O

-	O
0	O
.	O
111	O

-	O
0	O
.	O
145	O

Principal	O
Components	O
accounting	O
for	O
<	O
10	O
%	O
variance	O
and	O
vector	O
coefficients	O
<	O
0	O
.	O
1	O
are	O
not	O
shown	O
.	O

Alpha	O
diversity	O
measures	O
,	O
species	O
richness	O
(	O
the	O
number	O
of	O
different	O
OTUs	O
),	O
Pielou	O
’	O
s	O
evenness	O
(	O
the	O
skew	O
or	O
dominance	O
of	O
OTUs	O
),	O
Shannon	O
and	O
Inverse	O
Simpson	O
’	O
s	O
diversity	O
indices	O
,	O
were	O
calculated	O
for	O
each	O
sample	O
.	O

There	O
were	O
no	O
significant	O
differences	O
in	O
alpha	O
diversity	O
between	O
healthy	O
,	O
non	O
-	O
severe	O
and	O
severe	O
asthmatics	O
(	O
Fig	O
3A	O
).	O

A	O
Bray	O
Curtis	O
dissimilarity	O
matrix	O
was	O
calculated	O
and	O
PERMANOVA	O
(	O
Adonis	O
)	O
used	O
to	O
demonstrate	O
that	O
community	O
structure	O
was	O
significantly	O
different	O
between	O
disease	O
groups	O
and	O
they	O
explained	O
6	O
%	O
of	O
the	O
variance	O
in	O
community	O
structure	O
(	O
P	O
=	O
0	O
.	O
008	O
,	O
Fig	O
3B	O
).	O

Diversity	O
of	O
microbial	O
communities	O
in	O
healthy	O
,	O
non	O
-	O
severe	O
and	O
severe	O
asthmatics	O
.	O

A	O
.	O

Boxplot	O
of	O
alpha	O
diversity	O
measures	O
Species	O
Richness	O
and	O
Shannon	O
’	O
s	O
Diversity	O
Index	O
,	O
which	O
are	O
not	O
significantly	O
different	O
between	O
groups	O
.	O

B	O
Non	O
metric	O
multidimensional	O
scaling	O
of	O
Bray	O
Curtis	O
distance	O
split	O
by	O
group	O
(	O
stress	O
0	O
.	O
22	O
).	O

Here	O
PERMANOVA	O
(	O
Adonis	O
)	O
indicates	O
that	O
community	O
structure	O
is	O
significantly	O
associated	O
with	O
asthma	B-DS
classification	O
(	O
P	O
=	O
0	O
.	O
008	O
)	O
and	O
this	O
variable	O
explains	O
6	O
%	O
of	O
the	O
variance	O
.	O

Discussion	O

This	O
analysis	O
of	O
the	O
microbiota	B-OG
in	O
patients	O
with	O
non	O
-	O
severe	O
and	O
severe	O
asthma	B-DS
is	O
one	O
of	O
the	O
most	O
substantial	O
reported	O
so	O
far	O
.	O

We	O
defined	O
severe	O
asthma	B-DS
as	O
patients	O
who	O
remained	O
uncontrolled	O
despite	O
taking	O
sufficient	O
amounts	O
of	O
asthma	B-DS
medication	O
including	O
corticosteroids	O
,	O
often	O
as	O
systemic	O
doses	O
as	O
well	O
as	O
via	O
the	O
inhaled	O
route	O
.	O

Even	O
in	O
this	O
modest	O
number	O
of	O
subjects	O
,	O
we	O
found	O
clusters	O
of	O
severe	O
asthma	B-DS
such	O
as	O
those	O
with	O
poor	O
lung	O
function	O
,	O
oral	O
corticosteroid	O
use	O
and	O
sputum	O
eosinophilia	B-DS
.	O

We	O
found	O
that	O
there	O
were	O
marked	O
differences	O
in	O
the	O
distribution	O
of	O
Phyla	O
between	O
groups	O
.	O

Our	O
findings	O
in	O
patients	O
with	O
non	O
-	O
severe	O
asthma	B-DS
are	O
strongly	O
consistent	O
with	O
earlier	O
studies	O
showing	O
an	O
increase	O
in	O
Proteobacteria	B-OG
and	O
a	O
reduction	O
in	O
non	O
-	O
pathogenic	O
commensals	O
when	O
compared	O
to	O
controls	O
[	O
12	O
,	O
14	O
,	O
26	O
].	O

We	O
discovered	O
equally	O
distinctive	O
changes	O
in	O
the	O
severe	O
asthma	B-DS
group	O
.	O

Bacteroidetes	B-OG
and	O
Fusobacteria	B-OG
,	O
representing	O
non	O
-	O
pathogens	O
were	O
reduced	O
in	O
both	O
non	O
-	O
severe	O
and	O
severe	O
asthmatic	O
groups	O
compared	O
to	O
the	O
healthy	O
group	O
,	O
while	O
Firmicutes	B-OG
were	O
markedly	O
increased	O
in	O
severe	O
asthmatics	O
.	O

Amongst	O
the	O
Firmicutes	B-OG
,	O
we	O
also	O
found	O
that	O
2	O
Streptococcus	B-OG
spp	I-OG
.,	O
Streptococcus_23	O
and	O
Streptococcus_155	O
,	O
were	O
correlated	O
with	O
asthma	B-DS
severity	O
.	O

In	O
addition	O
,	O
one	O
OTU	O
identified	O
as	O
Prevotella	B-OG
spp	I-OG
.	O
showed	O
negative	O
correlation	O
with	O
asthma	B-DS
status	O
.	O

Though	O
alpha	O
diversity	O
measures	O
did	O
not	O
demonstrate	O
a	O
difference	O
between	O
asthma	B-DS
subgroups	O
,	O
there	O
were	O
small	O
significant	O
differences	O
in	O
the	O
whole	O
community	O
structure	O
as	O
determined	O
using	O
an	O
analysis	O
of	O
beta	O
diversity	O
.	O

Thus	O
,	O
the	O
airway	O
microbiota	B-OG
in	O
severe	O
asthma	B-DS
is	O
different	O
from	O
the	O
non	O
-	O
severe	O
asthma	B-DS
patient	O
,	O
which	O
is	O
in	O
turn	O
different	O
from	O
healthy	O
controls	O
.	O

Furthermore	O
,	O
non	O
-	O
severe	O
asthmatics	O
demonstrated	O
an	O
increase	O
in	O
Proteobacteria	B-OG
relative	O
to	O
either	O
healthy	O
controls	O
or	O
severe	O
asthmatics	O
.	O

In	O
the	O
study	O
of	O
Marri	O
et	O
al	O
[	O
38	O
],	O
who	O
also	O
used	O
induced	O
sputum	O
samples	O
from	O
10	O
non	O
-	O
asthmatic	O
and	O
10	O
adults	O
with	O
asthma	B-DS
not	O
taking	O
inhaled	O
or	O
oral	O
corticosteroid	O
therapy	O
at	O
the	O
time	O
of	O
the	O
study	O
,	O
a	O
greater	O
abundance	O
of	O
Proteobacteria	B-OG
,	O
particularly	O
Haemophilus	B-OG
,	O
and	O
lower	O
abundance	O
of	O
Firmicutes	B-OG
was	O
reported	O
.	O

The	O
increase	O
in	O
Proteobacteria	B-OG
confirmed	O
the	O
results	O
of	O
earlier	O
studies	O
[	O
12	O
,	O
13	O
]	O
using	O
bronchial	O
brushings	O
from	O
asthma	B-DS
patients	O
who	O
were	O
on	O
inhaled	O
corticosteroid	O
treatment	O
,	O
where	O
Haemophilus	B-OG
was	O
particularly	O
seen	O
to	O
be	O
increased	O
,	O
with	O
the	O
former	O
study	O
also	O
reporting	O
a	O
decrease	O
in	O
Prevotella	B-OG
.	O

Furthermore	O
,	O
our	O
previous	O
study	O
[	O
12	O
],	O
a	O
group	O
of	O
asthmatic	O
children	O
with	O
difficult	O
-	O
to	O
-	O
treat	O
asthma	B-DS
on	O
high	O
dose	O
inhaled	O
corticosteroids	O
,	O
an	O
increase	O
in	O
Proteobacteria	B-OG
/	O
Haemophilus	B-OG
and	O
Firmicutes	B-OG
/	O
Staphylococcus	B-OG
or	O
Streptococcus	B-OG
,	O
and	O
a	O
decrease	O
on	O
Bacteroidetes	B-OG
/	O
Prevotella	B-OG
were	O
observed	O
in	O
bronchoalveolar	O
lavage	O
fluid	O
samples	O
.	O

Our	O
current	O
data	O
focused	O
on	O
an	O
analysis	O
of	O
sputum	O
samples	O
from	O
patients	O
with	O
severe	O
asthma	B-DS
are	O
consistent	O
with	O
the	O
differences	O
in	O
phyla	O
/	O
genera	O
previously	O
reported	O
between	O
asthma	B-DS
and	O
controls	O
.	O

Recently	O
,	O
using	O
bronchial	O
brushings	O
from	O
the	O
lower	O
airways	O
,	O
Huang	O
et	O
al	O
.	O
have	O
reported	O
that	O
patients	O
with	O
severe	O
asthma	B-DS
were	O
significantly	O
enriched	O
in	O
Actinobacteria	B-OG
compared	O
to	O
healthy	O
control	O
subjects	O
or	O
patients	O
with	O
mild	O
-	O
to	O
-	O
moderate	O
asthma	B-DS
,	O
with	O
the	O
largest	O
differences	O
seen	O
in	O
a	O
member	O
of	O
the	O
Klebsiella	B-OG
genus	O
[	O
39	O
].	O

Whether	O
the	O
discrepancy	O
between	O
our	O
findings	O
and	O
that	O
of	O
Huang	O
et	O
al	O
.	O
is	O
due	O
to	O
differences	O
in	O
the	O
region	O
of	O
the	O
lung	O
is	O
unclear	O
at	O
present	O
and	O
would	O
necessitate	O
further	O
investigation	O
whereby	O
intra	O
-	O
subject	O
comparisons	O
are	O
done	O
of	O
bronchial	O
brushing	O
versus	O
induced	O
sputum	O
.	O

Asthma	B-DS
is	O
a	O
heterogeneous	O
syndrome	O
resulting	O
from	O
an	O
interaction	O
of	O
different	O
environmental	O
factors	O
[	O
such	O
as	O
allergens	O
,	O
smoking	O
and	O
medications	O
]	O
with	O
host	O
factors	O
to	O
produce	O
complex	O
phenotypic	O
manifestations	O
[	O
3	O
,	O
27	O
].	O

Phenotypic	O
complexity	O
can	O
be	O
simplified	O
by	O
statistical	O
procedures	O
such	O
as	O
principal	O
component	O
analysis	O
[	O
PCA	O
]	O
which	O
identifies	O
the	O
most	O
important	O
variables	O
and	O
their	O
correlations	O
.	O

PCA	O
of	O
the	O
phenotypic	O
data	O
led	O
to	O
the	O
definition	O
of	O
four	O
main	O
principal	O
components	O
.	O

The	O
first	O
2	O
clusters	O
had	O
characteristics	O
of	O
severe	O
asthma	B-DS
[	O
3	O
]	O
and	O
were	O
associated	O
with	O
the	O
3	O
bacterial	O
species	O
that	O
were	O
over	O
-	O
or	O
under	O
-	O
represented	O
in	O
severe	O
asthma	B-DS
.	O

Thus	O
,	O
in	O
Cluster	O
PC2	O
,	O
patients	O
on	O
oral	O
corticosteroid	O
therapy	O
with	O
an	O
atopic	O
background	O
,	O
sputum	O
eosinophilia	B-DS
and	O
airflow	O
obstruction	O
were	O
more	O
likely	O
to	O
be	O
associated	O
with	O
an	O
increase	O
of	O
Streptococcus_155	O
and	O
a	O
decrease	O
in	O
Prevotella_292	O
.	O

On	O
the	O
other	O
hand	O
,	O
Cluster	O
PC1	O
also	O
representing	O
a	O
severe	O
group	O
not	O
on	O
oral	O
corticosteroids	O
but	O
on	O
high	O
dose	O
inhaled	O
corticosteroids	O
and	O
long	O
-	O
acting	O
β	O
-	O
agonist	O
,	O
with	O
a	O
long	O
duration	O
of	O
asthma	B-DS
and	O
non	O
-	O
atopic	O
background	O
,	O
was	O
associated	O
with	O
an	O
increase	O
in	O
both	O
Streptococcus	B-OG
_23	O
and	O
Streptococcus_155	O
,	O
and	O
to	O
some	O
extent	O
with	O
a	O
reduction	O
in	O
Prevotella_292	O
.	O

The	O
greatest	O
association	O
with	O
an	O
increase	O
in	O
Streptococcus_155	O
and	O
Streptococcus_23	O
was	O
seen	O
in	O
Cluster	O
PC3	O
,	O
characterised	O
by	O
both	O
blood	O
and	O
sputum	O
eosinophilia	B-DS
,	O
but	O
with	O
a	O
lower	O
sputum	O
neutrophil	O
count	O
,	O
and	O
nasal	B-DS
disease	I-DS
,	O
with	O
an	O
increased	O
likelihood	O
of	O
being	O
on	O
oral	O
corticosteroids	O
.	O

These	O
associations	O
in	O
distinct	O
clusters	O
of	O
asthma	B-DS
may	O
reflect	O
the	O
influence	O
of	O
specific	O
elements	O
of	O
the	O
microbiota	B-OG
on	O
well	O
-	O
known	O
characteristics	O
of	O
severe	O
asthma	B-DS
such	O
as	O
eosinophilia	B-DS
,	O
chronic	B-DS
airflow	I-DS
obstruction	I-DS
and	O
corticosteroid	O
insensitivity	O
[	O
40	O
].	O

Alternatively	O
,	O
asthma	B-DS
treatments	O
[	O
such	O
as	O
corticosteroid	O
or	O
β	O
-	O
adrenergic	O
agonist	O
therapies	O
]	O
or	O
the	O
differences	O
between	O
asthma	B-DS
subtypes	O
may	O
select	O
for	O
particular	O
microorganisms	B-OG
.	O

Several	O
confounding	O
factors	O
particularly	O
in	O
the	O
severe	O
asthmatic	O
subjects	O
need	O
to	O
be	O
taken	O
into	O
consideration	O
.	O

First	O
,	O
the	O
effect	O
of	O
asthma	B-DS
treatments	O
on	O
the	O
airway	O
microbiota	B-OG
remains	O
unclear	O
.	O

In	O
addition	O
to	O
potential	O
unknown	O
effects	O
on	O
bacterial	O
persistence	O
and	O
growth	O
,	O
these	O
medications	O
may	O
alter	O
the	O
innate	O
immune	O
response	O
to	O
bacteria	B-OG
that	O
may	O
in	O
turn	O
determine	O
their	O
pathogenicity	O
.	O

By	O
definition	O
,	O
the	O
patients	O
with	O
severe	O
asthma	B-DS
that	O
we	O
studied	O
were	O
already	O
on	O
high	O
doses	O
of	O
inhaled	O
corticosteroids	O
,	O
often	O
on	O
oral	O
corticosteroids	O
.	O

However	O
,	O
none	O
were	O
on	O
antibiotic	O
therapy	O
or	O
had	O
been	O
in	O
the	O
past	O
6	O
weeks	O
,	O
as	O
this	O
was	O
one	O
of	O
the	O
major	O
entry	O
criteria	O
.	O

The	O
potential	O
effect	O
of	O
corticosteroids	O
on	O
the	O
lung	O
microbiota	B-OG
is	O
unclear	O
,	O
but	O
comparing	O
the	O
microbiota	B-OG
data	O
of	O
Marri	O
et	O
al	O
.	O
[	O
38	O
]	O
where	O
patients	O
with	O
asthma	B-DS
not	O
on	O
inhaled	O
corticosteroids	O
were	O
selected	O
with	O
those	O
of	O
Hilty	O
et	O
al	O
.	O
[	O
12	O
],	O
there	O
were	O
no	O
major	O
differences	O
that	O
would	O
indicate	O
an	O
effect	O
of	O
inhaled	O
corticosteroids	O
.	O

On	O
the	O
other	O
hand	O
,	O
in	O
the	O
small	O
study	O
of	O
the	O
lung	O
microbiome	O
in	O
patients	O
with	O
moderate	O
to	O
severe	O
COPD	B-DS
,	O
the	O
alterations	O
in	O
lung	O
microbiome	O
reported	O
may	O
have	O
been	O
accounted	O
for	O
by	O
inhaled	O
corticosteroid	O
therapy	O
[	O
41	O
].	O

The	O
other	O
important	O
observation	O
is	O
that	O
the	O
gut	O
microbiota	B-OG
has	O
been	O
reported	O
to	O
completely	O
metabolise	O
corticosteroids	O
such	O
as	O
prednisolone	O
,	O
beclomethasone	O
dipropionate	O
and	O
budesonide	O
,	O
but	O
the	O
effect	O
of	O
the	O
airway	O
microbiota	B-OG
in	O
this	O
context	O
remains	O
unknown	O
[	O
42	O
].	O

The	O
possibility	O
that	O
such	O
an	O
action	O
by	O
selected	O
bacteria	B-OG
to	O
preferentially	O
metabolise	O
corticosteroids	O
could	O
underlie	O
corticosteroid	O
insensitivity	O
in	O
severe	O
asthma	B-DS
has	O
not	O
been	O
tested	O
.	O

The	O
significance	O
of	O
the	O
changes	O
in	O
sputum	O
microbiota	B-OG
that	O
we	O
observed	O
in	O
severe	O
asthma	B-DS
suggests	O
the	O
need	O
for	O
further	O
investigation	O
.	O

Since	O
our	O
patients	O
with	O
severe	O
asthma	B-DS
may	O
be	O
classified	O
as	O
being	O
corticosteroid	O
-	O
insensitive	O
as	O
demonstrated	O
by	O
studies	O
on	O
peripheral	O
blood	O
mononuclear	O
cells	O
or	O
alveolar	O
macrophages	O
[	O
43	O
,	O
44	O
],	O
the	O
recent	O
study	O
by	O
Goleva	O
and	O
colleagues	O
on	O
bronchoalveolar	O
lavage	O
microbiota	B-OG
of	O
patients	O
defined	O
as	O
corticosteroid	O
-	O
resistant	O
and	O
corticosteroid	O
insensitive	O
is	O
of	O
interest	O
[	O
23	O
].	O

In	O
corticosteroid	O
-	O
resistant	O
patients	O
,	O
they	O
reported	O
an	O
increase	O
in	O
the	O
proportion	O
of	O
sequences	O
of	O
microorganisms	B-OG
in	O
the	O
phyla	O
Actinobacteria	B-OG
and	O
Proteobacteria	B-OG
,	O
and	O
reduced	O
sequences	O
for	O
the	O
genera	O
Prevotella	B-OG
and	O
Veillonella	B-OG
,	O
and	O
Phylum	O
Fusobacteria	B-OG
compared	O
to	O
normal	O
control	O
subjects	O
[	O
23	O
].	O

Our	O
data	O
are	O
partly	O
in	O
agreement	O
with	O
the	O
reported	O
reduction	O
in	O
Prevotella	B-OG
.	O

Goleva	O
et	O
al	O
further	O
showed	O
that	O
the	O
bacterium	O
that	O
was	O
overexpressed	O
in	O
these	O
patients	O
,	O
Haemophilus	B-OG
parainfluenzae	I-OG
,	O
can	O
directly	O
induce	O
corticosteroid	O
resistance	O
.	O

In	O
addition	O
,	O
Th	O
-	O
17	O
cells	O
may	O
be	O
induced	O
by	O
bacterial	B-DS
infections	I-DS
and	O
this	O
has	O
been	O
implicated	O
in	O
corticosteroid	O
insensitivity	O
[	O
45	O
,	O
46	O
].	O

Interestingly	O
,	O
the	O
sputum	O
culture	O
results	O
did	O
not	O
correlate	O
with	O
what	O
was	O
observed	O
from	O
the	O
16s	O
rRNA	O
analysis	O
with	O
positive	O
cultures	O
of	O
Haemophilus	B-OG
influenzae	I-OG
,	O
Moraxella	B-OG
catarrhalis	I-OG
and	O
Staphylococcus	B-OG
aureus	I-OG
being	O
most	O
commonly	O
observed	O
in	O
the	O
asthmatic	O
samples	O
.	O

This	O
may	O
not	O
be	O
surprising	O
given	O
the	O
fact	O
that	O
sputum	O
culture	O
results	O
will	O
depend	O
to	O
a	O
large	O
extent	O
on	O
the	O
media	O
on	O
which	O
the	O
bacteria	B-OG
are	O
grown	O
.	O

On	O
the	O
other	O
hand	O
,	O
DNA	O
-	O
based	O
assays	O
of	O
microbiota	B-OG
does	O
not	O
allow	O
one	O
to	O
determine	O
the	O
activity	O
of	O
members	O
of	O
the	O
microbial	O
community	O
.	O

A	O
more	O
comprehensive	O
approach	O
to	O
culturing	O
these	O
bacteria	B-OG
is	O
needed	O
.	O

One	O
potential	O
weakness	O
of	O
our	O
study	O
is	O
the	O
inevitable	O
contamination	O
of	O
the	O
upper	O
airway	O
microflora	B-OG
in	O
the	O
sputum	O
samples	O
.	O

However	O
,	O
this	O
contamination	O
would	O
have	O
been	O
similar	O
for	O
all	O
subjects	O
although	O
the	O
upper	O
airway	O
microbiota	B-OG
would	O
also	O
be	O
influenced	O
by	O
the	O
oral	O
and	O
dental	O
state	O
and	O
the	O
presence	O
of	O
comorbidities	O
such	O
as	O
rhinosinusitis	B-DS
,	O
laryngitis	B-DS
or	O
gastrooesophageal	B-DS
reflux	I-DS
.	O

The	O
microbiota	B-OG
we	O
found	O
in	O
this	O
study	O
is	O
quite	O
distinct	O
from	O
that	O
described	O
in	O
various	O
compartments	O
of	O
the	O
upper	O
airway	O
and	O
oral	O
cavity	O
such	O
as	O
saliva	O
,	O
nasopharynx	O
and	O
nose	O
[	O
47	O
,	O
48	O
].	O

Even	O
in	O
studies	O
that	O
have	O
directly	O
sampled	O
the	O
lower	O
airways	O
through	O
a	O
bronchoscope	O
for	O
brushings	O
,	O
biopsies	O
or	O
bronchoalveolar	O
lavage	O
fluid	O
,	O
there	O
may	O
have	O
been	O
contamination	O
brought	O
on	O
by	O
the	O
passage	O
of	O
the	O
bronchoscope	O
through	O
the	O
upper	O
airways	O
prior	O
to	O
getting	O
to	O
the	O
lower	O
airways	O
.	O

At	O
the	O
other	O
extreme	O
,	O
there	O
is	O
the	O
suggestion	O
that	O
the	O
bacteria	B-OG
found	O
in	O
the	O
lower	O
airway	O
represents	O
contamination	O
of	O
bacteria	B-OG
from	O
the	O
upper	O
airways	O
[	O
49	O
].	O

However	O
,	O
part	O
of	O
this	O
microbiota	B-OG
is	O
unique	O
representing	O
an	O
adaptation	O
towards	O
proliferation	O
in	O
the	O
lung	O
environment	O
[	O
50	O
].	O

It	O
is	O
important	O
that	O
such	O
a	O
study	O
was	O
performed	O
in	O
sputum	O
samples	O
because	O
this	O
is	O
the	O
most	O
non	O
-	O
invasive	O
way	O
of	O
obtaining	O
lower	O
airway	O
samples	O
relatively	O
safely	O
from	O
patients	O
,	O
and	O
will	O
represent	O
the	O
only	O
acceptable	O
method	O
of	O
obtaining	O
lower	O
airway	O
samples	O
from	O
all	O
patients	O
with	O
asthma	B-DS
.	O

While	O
the	O
16S	O
rRNA	O
gene	O
sequencing	O
approach	O
to	O
define	O
microbiota	B-OG
provides	O
us	O
with	O
the	O
bacterial	O
members	O
of	O
the	O
airway	O
microbiota	B-OG
,	O
it	O
does	O
not	O
provide	O
us	O
with	O
the	O
fungi	B-OG
and	O
viruses	B-OG
potentially	O
present	O
in	O
the	O
lower	O
airways	O
.	O

Their	O
potential	O
contribution	O
therefore	O
is	O
missed	O
by	O
using	O
this	O
approach	O
.	O

Another	O
limitation	O
of	O
our	O
cross	O
-	O
sectional	O
study	O
is	O
that	O
we	O
are	O
looking	O
at	O
a	O
single	O
time	O
point	O
and	O
therefore	O
are	O
restricted	O
in	O
terms	O
of	O
the	O
dynamic	O
nature	O
of	O
the	O
microbiota	B-OG
in	O
severe	O
asthma	B-DS
.	O

Longitudinal	O
studies	O
would	O
be	O
advantageous	O
but	O
far	O
from	O
trivial	O
when	O
balancing	O
the	O
clinical	O
care	O
of	O
patients	O
with	O
such	O
severe	O
disease	O
and	O
repeated	O
invasive	O
sampling	O
.	O

In	O
addition	O
,	O
dormancy	O
is	O
common	O
in	O
microbial	O
communities	O
and	O
activity	O
of	O
community	O
members	O
ideally	O
requires	O
a	O
direct	O
measure	O
of	O
activity	O
such	O
as	O
RNA	O
,	O
protein	O
or	O
metabolic	O
assays	O
or	O
serial	O
sampling	O
(	O
requiring	O
longitudinal	O
studies	O
)	O
that	O
we	O
were	O
unable	O
to	O
perform	O
here	O
.	O

Finally	O
,	O
there	O
are	O
other	O
alternative	O
analytical	O
methods	O
available	O
in	O
the	O
microbiome	O
literature	O
that	O
could	O
have	O
been	O
used	O
in	O
our	O
study	O
,	O
but	O
we	O
have	O
here	O
restricted	O
ourselves	O
to	O
the	O
most	O
commonly	O
used	O
methods	O
in	O
the	O
absence	O
of	O
bench	O
-	O
marking	O
studies	O
.	O

For	O
example	O
,	O
there	O
are	O
many	O
different	O
and	O
novel	O
statistical	O
tests	O
available	O
for	O
comparing	O
OTUs	O
and	O
other	O
phylogenetic	O
levels	O
in	O
microbiome	O
studies	O
,	O
but	O
no	O
bench	O
-	O
marking	O
.	O

We	O
have	O
therefore	O
resorted	O
to	O
use	O
a	O
well	O
-	O
established	O
statistical	O
test	O
corrected	O
for	O
multiple	O
testing	O
.	O

In	O
summary	O
,	O
we	O
have	O
shown	O
that	O
in	O
severe	O
asthma	B-DS
,	O
there	O
is	O
a	O
distinct	O
alteration	O
of	O
the	O
sputum	O
microbiota	B-OG
with	O
a	O
greater	O
prominence	O
of	O
Firmicutes	B-OG
(	O
including	O
2	O
Streptococcal	O
OTUs	O
,	O
and	O
a	O
lower	O
prominence	O
of	O
Bacteroidetes	B-OG
,	O
particularly	O
Prevotella	B-OG
spp	I-OG
.	O

These	O
bacterial	O
OTUs	O
were	O
related	O
to	O
distinct	O
components	O
of	O
the	O
severe	O
asthma	B-DS
syndrome	O
,	O
particularly	O
those	O
relating	O
to	O
the	O
use	O
of	O
oral	O
corticosteroids	O
.	O

Analysis	O
of	O
16S	O
rRNA	O
gene	O
sequences	O
differentiates	O
poorly	O
between	O
different	O
streptococcal	O
species	O
,	O
and	O
further	O
classification	O
by	O
typing	O
additional	O
polymorphic	O
loci	O
[	O
18	O
]	O
as	O
well	O
as	O
cultures	O
of	O
streptococcal	O
isolates	O
is	O
desirable	O
in	O
future	O
studies	O
.	O

In	O
addition	O
,	O
the	O
potential	O
role	O
of	O
these	O
streptococcal	O
species	O
in	O
the	O
pathogenesis	O
of	O
severe	O
asthma	B-DS
will	O
need	O
further	O
investigation	O
.	O

